stockrow
Friday 6 November 2026
Export RLYB’s income statement to Excel — free account
Rallybio Corporation
RLYB Healthcare Biotechnology
Rallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
15.74
0.16
−1.01%
Follow RLYB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 34.52% | 64.86% | (14.98%) | (15.01%) |
+8 more TTM periods Free account |
|
| 32.85% | 61.12% | (13.90%) | (13.77%) | ||
ROIC |
(944.36%) | (1,052.03%) | (576.66%) | (641.77%) | |
Return on Tangible Assets |
29.31% | 48.62% | (15.83%) | (15.74%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
5.42 | 4.69 | (4.85) | (5.30) | |
Free Cash Flow |
30.99 | 26.71 | (27.59) | (29.81) | |
| Other line items | |||||
Cash ROIC |
16.93% | 14.26% | (28.42%) | (26.46%) | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.05) | (0.03) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,951.40% | 2,284.03% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 1,893.01% | 1,669.58% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 471.79% | 619.35% | |
Operating CF/Net income |
1.16 | 0.59 | 3.53 | 3.32 | |
Depreciation/Fixed assets |
0.00 | 0.00 | (17.35) | (20.91) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.15 | 0.15 | |
Operating CF per Share |
5.42 | 4.69 | (4.85) | (5.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026